PRISMA Review Synthesizes Protein Intake and Resistance Training Guidance for Clinical Populations, Including GLP-1 Users

Standard dietary protein intake (0.8 g/kg/day) and physical activity (150 min/week) guidelines are often applied broadly, yet specific clinical populations require tailored approaches. Patients on GLP-1 receptor agonists (GLP-1 RAs) for obesity or type 2 diabetes experience substantial weight loss, often including significant lean body mass. This raises concerns about sarcopenia and protein inadequacy, as appetite suppression may reduce protein intake. Current guidance lacks specificity for these vulnerable groups.

This study conducted a PRISMA-guided rapid review to synthesize observational and randomized evidence on protein intake and resistance training in diverse clinical populations. The review aimed to identify specific recommendations beyond general guidelines, particularly for groups like those on GLP-1 RAs. It systematically evaluated existing literature to address the nuanced nutritional and exercise needs of patients with various health conditions.

The full specific findings of this rapid review were not provided in the available abstract. However, the review's primary objective was to synthesize existing evidence on optimal protein intake and resistance training strategies across various clinical populations. > It specifically aims to address the critical challenge of lean body mass preservation in patients undergoing significant weight loss, such as those treated with GLP-1 receptor agonists. The review is expected to offer nuanced recommendations for protein intake and exercise protocols tailored to specific patient needs, moving beyond generalized nutritional and activity guidelines.